(Q37903590)

25 August 2017

1 reference

title

A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: what is the published evidence? (English)

1 reference

25 August 2017

1 reference

1 reference

Eugenio Piro

1

1 reference

25 August 2017

Stefano Molica

series ordinal

2

1 reference

25 August 2017

language of work or name

1 reference

21 July 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

126

1 reference

25 August 2017

issue

3

1 reference

25 August 2017

page(s)

163-168

1 reference

Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens

25 August 2017

cites work

1 reference

Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study

21 January 2018

1 reference

Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.

21 January 2018

1 reference

Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents

21 January 2018

1 reference

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

21 January 2018

1 reference

Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors

21 January 2018

1 reference

Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: efficacy and safety in patients with renal function impairment

21 January 2018

1 reference

Bortezomib in relapsed multiple myeloma: results of a non-interventional study by office-based haematologists

21 January 2018

1 reference

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

21 January 2018

1 reference

Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study.

21 January 2018

1 reference

Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment

21 January 2018

1 reference

VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA s

21 January 2018

1 reference

Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease

21 January 2018

1 reference

Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

21 January 2018

1 reference

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group

21 January 2018

1 reference

Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib

21 January 2018

1 reference

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

21 January 2018

1 reference

Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000328417

1 reference

25 August 2017

1 reference